New drug interventions in Alzheimer's disease.
Stern
G M
GM
Department of Neurology, Middlesex Hospital School of Medicine, University College London, UK.
D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D001127:Arginine Vasopressin / Q000031:analogs & derivatives / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D005677:G(M1) Ganglioside / Q000627:therapeutic use; D006801:Humans; D011939:Mental Recall / Q000187:drug effects; D009483:Neuropsychological Tests; D010830:Physostigmine / Q000627:therapeutic use; D010865:Pilot Projects; D011950:Receptors, Cholinergic / Q000187:drug effects; D013619:Tacrine / Q000627:therapeutic use
D002800:Cholinesterase Inhibitors; D011950:Receptors, Cholinergic; D001127:Arginine Vasopressin; C015119:argipressin, des-GlyNH2(9)-; D005677:G(M1) Ganglioside; D013619:Tacrine; D010830:Physostigmine